FGF-23

FGF-23 Molekülinformation

Englischer Name	Fibroblast growth factor 23	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1	Target-Alias	HFTC2，Tumor-Derived Hypophosphatemia Inducing Factor，UNQ3027/PRO9828，Tumor-derived hypophosphatemia-inducing factor，HYPF，FGF23，Fibroblast Growth Factor 23，Phosphatonin，FGF-23，HPDR2，PHPTC，ADHR，FGFN
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Fibroblast growth factor 23
Target-Alias	HFTC2，Tumor-Derived Hypophosphatemia Inducing Factor，UNQ3027/PRO9828，Tumor-derived hypophosphatemia-inducing factor，HYPF，FGF23，Fibroblast Growth Factor 23，Phosphatonin，FGF-23，HPDR2，PHPTC，ADHR，FGFN
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Approved

FGF-23 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
FG3-H52H3	Human	HEK293	Human FGF-23 (R179Q) Protein, His Tag, low endotoxin				In den Warenkorb legen

Gesamtmenge1

Produktanfrage

FGF-23 Molekülhintergrund

Fibroblast growth factor 23 (FGF23) is is an endocrine member of the family of FGFs and mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF23 can exert several endocrine functions, such as acting as a hormone on the kidney, stimulating phosphate excretion and suppressing formation of 1,25(OH)2D3, active vitamin D. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. FGF23 and phosphate have been revealed to be factors relevant in cancer. FGF23 is particularly significant for those forms of cancer primarily affecting bone (e.g., multiple myeloma) or characterized by bone metastasis.

FGF-23 Molekülalias

FGF23,HYPF,FGF-23,ADHR,HPDR2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
KK-8123	KK8123; KK-8123	Phase 2 Clinical	Kyowa Kirin Inc	Familial Hypophosphatemic Rickets	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Burosumab	KRN-23; UX-023	Approved	Kyowa Hakko Kirin Co Ltd	Crysvita, 麟平	EU	Hypophosphatemia, Familial	Kyowa Kirin Holdings Bv	2018-02-19	Familial Hypophosphatemic Rickets; Fibrous Dysplasia of Bone; Genetic Diseases, X-Linked; Hypophosphatemia; Hypophosphatemia, Familial; Nevus, Sebaceous of Jadassohn; Osteomalacia	Details